Subcutaneous Immunoglobulin (SCIG) Market: Major Trends Reshaping the Future of the Industry

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Subcutaneous Immunoglobulin (SCIG) Industry Market Size Be by 2025?
Recent years have seen a swift expansion of the subcutaneous immunoglobulin (SCIG) market. The market, which stood at $12.72 billion in 2024, is projected to rise to $14.52 billion by 2025, reflecting a compound annual growth rate (CAGR) of 14.1%. The remarkable growth during the past period is linked to factors such as the growing incidence of immunodeficiency disorders, an increase in patient preference for home care, improved therapeutic effectiveness, the increase in awareness and diagnoses rates, as well as enhancements in favorable reimbursement policies.

What's the Long-Term Growth Forecast for the Subcutaneous Immunoglobulin (SCIG) Market Size Through 2029?
Predictions show the subcutaneous immunoglobulin (SCIG) market growing rapidly in the coming years, reaching a market value of $24.29 billion in 2029 with a compound annual growth rate (CAGR) of 13.7%. Factors contributing to the predicted growth include an increase in neurological disorders, a rise in autoimmune diseases, and a higher acceptance level and understanding of immunoglobulin therapy. Other contributing factors are the growing uses of subcutaneous immunoglobulin in neurology and dermatology and improved healthcare facilities. The market growth will also be propelled by advancements in drug delivery systems, a higher demand for home infusion therapies, progress in antibody therapy, and innovations in SCIG formulations.

View the full report here:
https://www.thebusinessresearchcompany.com/report/subcutaneous-immunoglobulin-scig-global-market-report

What Are the Key Growth Drivers Fueling the Subcutaneous Immunoglobulin (SCIG) Market Expansion?
The subcutaneous immunoglobulin market is impressively expanding due to the surge in cases of secondary immunodeficiency diseases. These diseases weaken the immune system, not because of the immune system itself, but due to external factors such as aging, immunosuppressive treatments, and exposure to environmental toxins. Subcutaneous immunoglobulin therapy offers antibodies that enhance the compromised immune system, particularly in chronic disorders like HIV or autoimmune diseases, thus preventing infections and maintaining immunological function during treatment. As evidence, the UK Health Security Agency, a government-based agency in the UK, recorded a 22% increase in new HIV diagnoses in England in 2022 from the previous year which directly implies an increase in secondary immunodeficiency diseases hence propelling the subcutaneous immunoglobulin market. The subcutaneous immunoglobulin market is further gaining traction due to the escalating number of neurological disorders. Neurological disorders are disturbances in the nervous system resulting from abnormalities in various parts of it, like the brain, spinal cord, or peripheral nerves which include, Alzheimer's dementia, brain tumors, etc. The rise in neurological disorders is due to several reasons such as aging, environmental toxins, genetics, and lifestyle changes. Subcutaneous immunoglobulin therapy aids in managing neurological disorders by supplying antibodies that normalize the immune response, reduce inflammation and provide stability to neuromuscular junctions, potentially slowing the progression of these disorders and improving symptoms. This is validated by estimations from the Alzheimer's Association, a nonprofit voluntary health group, which states that the number of Americans aged 65 and above currently living with Alzheimer's dementia is 6.5 million and is expected to reach 13.8 million by 2060. Thus, the upswing in neurological disorder cases is driving the growth of the subcutaneous immunoglobulin market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15935&type=smp

What Are the Key Trends Driving Subcutaneous Immunoglobulin (SCIG) Market Growth?
Leading firms in the subcutaneous immunoglobulin market are advancing in the creation of subcutaneous human-klhw, a distinct blend that includes human immune globulins (Ig) to enhance the immune system. This unique formulation is applied subcutaneously and is engineered to address primary immunodeficiency disorders in the human body. For instance, Grifols S.A., a pharmaceutical firm based in Spain, introduced XEMBIFY 20% subcutaneous immunoglobulin (SCIG) in March 2022. This product specifically caters to primary immunodeficiency, filling a crucial medical requirement for individuals with compromised immune systems. XEMBIFY, as a ready-to-use formula, streamlines the treatment process and heightens patient comfort. It can remain stable at room temperature for as long as 24 months, eliminating the necessity for cooling during storage and transit which is highly beneficial in various healthcare environments.

How Is the Subcutaneous Immunoglobulin (SCIG) Market Segmented?
The subcutaneous immunoglobulin (SCIG) market covered in this report is segmented -

1) By Product Type: Immunoglobulin A (IgA), Immunoglobulin G (IgG), Immunoglobulin M (IgM)
2) By Application: Primary Immunodeficiency Disorders, Autoimmune Diseases, Neurological Disorders, Other Applications
3) By End-Use: Clinics, Hospitals, Homecare, Other End-Uses

Subsegments:
1) By Immunoglobulin A (IgA): IgA1, IgA2
2) By Immunoglobulin G (IgG): IgG1, IgG2, IgG3, IgG4
3) By Immunoglobulin M (IgM): Pentameric IgM, Hexameric IgM

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=15935&type=smp

Which Companies Are Leading the Charge in Subcutaneous Immunoglobulin (SCIG) Market Innovation?
Major companies operating in the subcutaneous immunoglobulin (SCIG) market are Pfizer Inc., Johnson & Johnson, Prothena Corporation plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Baxter International Inc., CSL Behring, Lonza Group, Grifols S.A., Octapharma AG, Dr. Reddy's Laboratories, Intas pharmaceutical Ltd., Emergent BioSolutions Inc., Kedrion Biopharma, LFB group, Biotest AG, Argenx SE, Bio Products Laboratory Ltd., ADMA Biologics Inc., Sino Biological Inc., Bharat Serums and Vaccines Limited (BSV), Kamada Pharmaceuticals, CinnaGen Co., Shire plc

Which Regions Are Leading the Global Subcutaneous Immunoglobulin (SCIG) Market in Revenue?
North America was the largest region in the subcutaneous immunoglobulin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the subcutaneous immunoglobulin (SCIG) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15935

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.